COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 5, 2007, Pages 526-530

  Cascinu, Stefano ^a,c   Scartozzi, Mario ^a   Carbonari, Giovanna ^a   Pierantoni, Chiara ^a   Verdecchia, Lorena ^a   Mariani, Cinzia ^b   Squadroni, Michela ^a   Antognoli, Stefania ^a   Silva, Rosa Rita ^b   Giampieri, Riccardo ^a   Berardi, Rossana ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Profili   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

COX 2; NF KB; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BIOCHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 35148853151     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318054675c     Document Type: Article

References (20)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
2. Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000;58:215-218.
3. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol. 2002;29:25-35.
4. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783.
5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
6. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
7. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22:2610-2616.
8. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76.
9. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
10. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003;7:207-222.
11. Tseng WW, Deganutti A, Chen MN, et al. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. Gastrointest Surg. 2002;6:838-843.
12. Sclabas GM, Fujioka S, Schmidt C, et al. NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer. 2003;33:15-26.
13. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003;3:107-112.
14. Jiang JG, Tang JB, Chen CL, et al. Expression of cyclooxigenase-2 in human esophageal squamous cell carcinoma. World J Gastroenterol 2004;10:2168-2173.
15. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
16. Blanke CD, Masferrer JL. Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials. Prog Exp Tumor Res. 2003;37:243-260.
17. Lipton A, Harvey H, Witters L, et al. Gemcitabine/irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park). 2004;18:43-45.
18. El-Rayes BF, Zalupski MM, Shields AF, et al. A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
19. Solomon SD, McMurray JV, Pfeffer MA, et al. The adenoma prevention with celecoxib (APC) Study Investigators: cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
20. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(suppl 16):1.